Development of Neutralizing Monoclonal Antibodies for Oncogenic Human Papillomavirus Types 31, 33, 45, 52, and 58

類似資料

• Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
  著者:: Mariz, Filipe Colaço, 等
  出版事項: (2020)
• Burden of Human Papillomavirus (HPV)-Related Cancers Attributable to HPVs 6/11/16/18/31/33/45/52 and 58
  著者:: de Sanjosé, Silvia, 等
  出版事項: (2019)
• Recurrence of Genital Infections With 9 Human Papillomavirus (HPV) Vaccine Types (6, 11, 16, 18, 31, 33, 45, 52, and 58) Among Men in the HPV Infection in Men (HIM) Study
  著者:: Pamnani, Shitaldas J, 等
  出版事項: (2018)
• Variant-Specific Persistence of Infections with Human Papillomavirus Types 31, 33, 45, 56 and 58 and Risk of Cervical Intraepithelial Neoplasia
  著者:: Xi, Long Fu, 等
  出版事項: (2016)
• Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58
  著者:: Brendle, Sarah A., 等
  出版事項: (2010)